Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-03-15

Clinical Trial Update: A Study of E7389 in Advanced/Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating eribulin (E7389) for advanced or metastatic breast cancer; results from the study were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Halaven (eribulin)

Snippet

Sponsor: Eisai Inc. | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-03-15